Ridolo Erminia, Incorvaia Cristoforo, Martignago Irene, Pessina Laura, Lauretani Fulvio, Loperfido Luciano, Riario-Sforza Gian Galeazzo, Broglia Annalisa, Gritti Bruna L, Panella Lorenzo
1Department of Medicine and Surgery Clinical, University of Parma, Via Gramsci 14, 43126 Parma, Italy.
Cardiac/Pulmonary Rehabilitation, ASST Pini/CTO, Via Bignami 1, 20126 Milan, Italy.
Clin Mol Allergy. 2018 May 16;16:12. doi: 10.1186/s12948-018-0090-y. eCollection 2018.
Based on meta-analyses results, it is currently acknowledged that there is an increased risk of pneumonia in patients with chronic obstructive pulmonary disease (COPD) undergoing inhaled corticosteroids (ICS) treatment. However, this is not found to be true in those with asthma. No data on this risk are available for COPD patients involved in pulmonary rehabilitation program (PR).
For 1 year, we prospectively studied 2 cohorts of COPD patients-undergoing PR and not undergoing PR. The first group included 438 patients undergoing PR of which 353 were treated with ICS, and 85 were treated with bronchodilators only. The second group was comprised of 76 COPD patients who were treated with ICS, but not PR. The control group consisted of 49 ICS-treated patients with asthma. The diagnosis of pneumonia, when suspected, had to be confirmed with a chest x-ray.
Overall, 6 cases of pneumonia were diagnosed in the first study group: 5 ICS-treated patients and 1 patient treated only with bronchodilators. This corresponded to a rate of 1.41 and 1.17%, respectively, compared to a rate of 6.6% in COPD patients not treated with PR, which was significantly higher (p = 0.029) than that in the first study group. No case of pneumonia was registered among patients with asthma.
These findings suggest that a significantly lower incidence of pneumonia is found in COPD patients treated with ICS and PR than in patients treated with ICS but not with PR. This observation deserves to be investigated in large populations of PR-treated COPD patients, possibly in multi-centric cohort studies.
基于荟萃分析结果,目前公认慢性阻塞性肺疾病(COPD)患者接受吸入性糖皮质激素(ICS)治疗时肺炎风险增加。然而,在哮喘患者中未发现这种情况。对于参与肺康复计划(PR)的COPD患者,尚无关于此风险的数据。
我们前瞻性地研究了2组COPD患者,为期1年,一组接受PR,另一组未接受PR。第一组包括438例接受PR的患者,其中353例接受ICS治疗,85例仅接受支气管扩张剂治疗。第二组由76例接受ICS治疗但未接受PR的COPD患者组成。对照组由49例接受ICS治疗的哮喘患者组成。疑似肺炎时,必须通过胸部X光确诊。
总体而言,在第一个研究组中诊断出6例肺炎:5例接受ICS治疗的患者和1例仅接受支气管扩张剂治疗的患者。这分别对应1.41%和1.17%的发生率,而未接受PR治疗的COPD患者发生率为6.6%,显著高于第一个研究组(p = 0.029)。哮喘患者中未登记到肺炎病例。
这些发现表明,接受ICS和PR治疗的COPD患者肺炎发生率明显低于仅接受ICS治疗但未接受PR的患者。这一观察结果值得在大量接受PR治疗的COPD患者中进行研究,可能在多中心队列研究中进行。